Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding This to DIPSS Helps HCT Outcome Prediction

Biol Blood Marrow Transplant; ePub 2017 Sep 29; Bannow, et al

Adding cytogenetics, thrombocytopenia, and red cell transfusion dependence as risk factors appears to improve the Dynamic International Prognostic Scoring System (DIPSS), according to a study involving 233 individuals with myelofibrosis (MF). Investigators sought to determine if the enhanced system would predict post- hematopoietic cell transplantation (HCT) outcomes better than DIPSS-alone. Among the results:

  • 5-year overall survival rate for patients with low/int-1 risk MF was 78%.
  • Relapse and treatment-related mortality rates were 5% and 20%, respectively.
  • 5-year overall survival rate in patients with high-risk MF was 35%.
  • Relapse and treatment-related mortality rates were 28% and 40%, respectively.
  • HCT-comorbidity index of ≥3 was linked with higher non-relapse and overall mortality, and lower relapse-free survival.
  • Older patients were 3 times more likely to experience relapse.
  • At a median follow-up of 8 years, ~half of patients had survived.

The authors noted that the findings may help improve the ability to advise patients about transplant timing.

Citation:

Bannow B, Salit R, Storer B, et al. Hematopoietic cell transplantation for myelofibrosis: DIPSS plus risk predicts post-transplant outcomes. [Published online ahead of print September 29, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.09.016.

This Week's Must Reads

Undertreatment of Newly-Diagnosed MM Evaluated, Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Fakhri, et al

Blacks Fare Better After This Type of Transplant , Biol Blood Marrow Transplant.; ePub 2018 Jan 25; Solomon, et al

Aminocaproic Acid, Bleeding Complications Assessed, Leuk Lymphoma; ePub 2018 Feb 9; Juhl, Roddy, et al

Medication Adherence’s Impact on Outcomes in MM , Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Gupta, et al

FDA Approves Rebinyn to Treat Hemophilia B, Novo Nordisk news release; 2018 Feb 8

Must Reads in Myelodysplastic Syndrome

Undertreatment of Newly-Diagnosed MM Evaluated, Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Fakhri, et al

Blacks Fare Better After This Type of Transplant , Biol Blood Marrow Transplant.; ePub 2018 Jan 25; Solomon, et al

Medication Adherence’s Impact on Outcomes in MM , Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Gupta, et al

Predicting Long-Term Survival After Allo-HCT , Biol Blood Marrow Transplant; ePub 2018 Jan 21; Patel, et al

Advance Directives Underused in These Patients, Biol Blood Marrow Transplant; ePub 2018 Jan 23; Cappell, et al